- Home
- ATOS vs TIMB Comparison
ATOS vs TIMB Comparison
Compare ATOS & TIMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- TIMB
- Stock Information
- Founded
- ATOS 2009
- TIMB 1998
- Country
- ATOS United States
- TIMB Brazil
- Employees
- ATOS N/A
- TIMB N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- TIMB Telecommunications Equipment
- Sector
- ATOS Health Care
- TIMB Telecommunications
- Exchange
- ATOS Nasdaq
- TIMB Nasdaq
- Market Cap
- ATOS 112.7M
- TIMB 94.1M
- IPO Year
- ATOS 2012
- TIMB 1998
- Fundamental
- Price
- ATOS $1.01
- TIMB $22.10
- Analyst Decision
- ATOS Strong Buy
- TIMB Hold
- Analyst Count
- ATOS 3
- TIMB 4
- Target Price
- ATOS $6.25
- TIMB $20.17
- AVG Volume (30 Days)
- ATOS 762.2K
- TIMB 307.6K
- Earning Date
- ATOS 11-11-2025
- TIMB 11-04-2025
- Dividend Yield
- ATOS N/A
- TIMB 6.32%
- EPS Growth
- ATOS N/A
- TIMB 16.41
- EPS
- ATOS N/A
- TIMB 0.27
- Revenue
- ATOS N/A
- TIMB $4,779,664,328.00
- Revenue This Year
- ATOS N/A
- TIMB $8.13
- Revenue Next Year
- ATOS N/A
- TIMB $5.28
- P/E Ratio
- ATOS N/A
- TIMB $15.95
- Revenue Growth
- ATOS N/A
- TIMB 5.32
- 52 Week Low
- ATOS $0.55
- TIMB $11.32
- 52 Week High
- ATOS $1.66
- TIMB $22.47
- Technical
- Relative Strength Index (RSI)
- ATOS 77.26
- TIMB 60.63
- Support Level
- ATOS $0.81
- TIMB $21.27
- Resistance Level
- ATOS $0.90
- TIMB $22.47
- Average True Range (ATR)
- ATOS 0.04
- TIMB 0.29
- MACD
- ATOS 0.02
- TIMB 0.00
- Stochastic Oscillator
- ATOS 83.33
- TIMB 69.17
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About TIMB TIM S.A. (Each representing 5)
TIM, which is 67%-owned by Telecom Italia, is the third largest wireless carrier in Brazil, with 62 million subscribers, equal to about 24% of the market. The firm also owns 49% of I-Systems, an infrastructure partnership that is expanding its network footprint across Brazil. I-Systems can provide broadband service to about 9 million locations, equal to 10%-15% of the country. TIM leases capacity on the venture's network to serve retail broadband customers under the UltraFibra brand. TIM also resells fiber network access from other providers, including Oi's former infrastructure business V.tal. In total, TIM claims it can offer fixed broadband service to about 16 million locations.